Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting tumor-intrinsic S100A1 augments antitumor immunity and potentiates immunotherapy efficacy

ABSTRACT: Targeting tumor-intrinsic S100A1 augments antitumor immunity and potentiates immunotherapy efficacy

PROVIDER: PRJNA1205386 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31866725_1.fastq.gz	Fastqsanger.gz
	SRR31866725_2.fastq.gz	Fastqsanger.gz
	SRR31866726_1.fastq.gz	Fastqsanger.gz
	SRR31866726_2.fastq.gz	Fastqsanger.gz
	SRR31866727_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Targeting tumor-intrinsic S100A1 augments antitumor immunity and potentiates immunotherapy efficacy

Project description:Immune checkpoint blockade (ICB) has revolutionized cancer treatment, but the therapeutic response is highly heterogeneous. A potential mode of resistance is tumor-intrinsic mechanisms leading to an immunosuppressive tumor microenvironment. However, the underlying interactive network remains elusive and the generalizable biomarkers and targeting strategies are still lacking. Here, we uncovered the potential of plasma S100 calcium-binding protein A1 (S100A1) in determining ICB efficacy based on liquid biopsy of patients with lung cancer. Muti-omics and functional studies suggested that tumor-intrinsic S100A1 expression correlates with an immunologically cold TME and resistance to ICB. Mechanistic investigations demonstrated that interfering with tumor-intrinsic S100A1/ubiquitin-specific protease 7/p65/granulocyte-macrophage colony-stimulating factor (GM-CSF) modulatory axis could potentiate an inflamed TME via promoting M1-like macrophage polarization and T cell function. GM-CSF priming was sufficient to enhance ICB response in tumors with high S100A1 expression. These findings defined S100A1 as a potential biomarker and a novel synergistic target for cancer immunotherapy.

2025-03-26 | GSE285657 | GEO

Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy

Project description:In this project, we transfected MC38 cells with Flag-tagged Mbtps1 or vector control. After that, we performed immunoprecipitation–mass spectrometry analysis to search the interacting proteins of MBTPS1. In our study, We observed that the loss of membrane-bound transcription factor site-1 protease (MBTPS1) in tumor cells enhanced antitumor immunity and potentiated anti-PD-1 therapy. Mechanistic studies revealed that tumor cell-intrinsic MBTPS1 competed with USP13 for binding to STAT1, thereby disrupting USP13-dependent deubiquitination and stabilization of STAT1. MBTPS1 deficiency induced CXCR3+ CD8+ T cell infiltration by upregulating STAT1-transcribed chemokines including CXCL9, CXCL10 and CXCL11. Notably, the regulatory role of MBTPS1 in antitumor immunity operates independently of its classic function in cleaving membrane-bound transcription factors. Collectively, our results provide a theoretical basis for MBTPS1 as a potential immunotherapy target and also as a predictor of immunotherapy efficacy.

2025-04-11 | PXD053978 | Pride

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer

Project description:CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer

| PRJNA1039833 | ENA

Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity

Project description:Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity

| PRJNA1121232 | ENA

Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity

Project description:Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity

| PRJNA864795 | ENA

Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity

Project description:DNA damage is a prevalent event within the tumor microenvironment, significantly influencing cancer initiation, progression, metastasis, and immune cell functionality. Here, we observed that oxidative stress induces DNA damage in tumor-associated dendritic cells (TADCs), leading to the activation of the serine/threonine kinase WEE1, which facilitates DNA repair. Notably, this DNA damage also acts as a stimulus for DC activation. Pharmacological inhibition of WEE1 activates TADCs via the cGAS/STING pathway, resulting in an enhanced antitumor immune response and improved tumor control. Furthermore, WEE1 inhibition augments the efficacy of DC vaccines and work synergistically with immune checkpoint blockade therapy. These findings underscore the critical role of WEE1-mediated signaling in DNA damage repair in immune cells in the tumor microenvironment, which in turn dampens the antitumor immune response. Thus, targeting WEE1 in DCs presents a promising strategy to enhance DC-mediated T cell activation and improve the effectiveness of cancer immunotherapy strategies.

2025-04-11 | GSE269330 | GEO

Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity [scRNA-Seq]

2025-04-11 | GSE269559 | GEO

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

Project description:A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

| PRJNA690718 | ENA

Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity [scRNA-Seq]

Project description:Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity [scRNA-Seq]

| PRJNA1122520 | ENA

Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages

Project description:Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages

| PRJNA1015572 | ENA